Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy over ...
Immunologic factors were highly significant predictors of therapy response in the GeparSixto trial, particularly in patients treated with Cb. After further standardization, they could be included in ...
Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin ...
Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study Adult patients with measurable, locally ...
Treatment Options for Relapsed Small-Cell Lung Cancer: What Progress Have We Made? The following represents disclosure information provided by authors of this manuscript. All relationships are ...
Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group The prognosis of acute- and lymphoma-type adult T-cell ...
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer The ideas and opinions expressed in this Data Supplement do ...
Detecting Disabilities in Older Patients With Cancer: Comparison Between Comprehensive Geriatric Assessment and Vulnerable Elders Survey-13 Patients with malignant glioma at progression after standard ...
Physical, Psychosocial, Relationship, and Economic Burden of Caring for People With Cancer: A Review
Protecting Patient Access to Oral Cancer Drugs in the United States The aim of this article is to provide an overview of the issues faced by caregivers of people diagnosed with cancer, with a ...
The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial demonstrated that the addition of oxaliplatin to fluorouracil plus leucovorin (FULV) improved disease-free survival (DFS) in ...
Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor ...
Between 2003 and 2005, 225 adult patients (median age, 31 years; range, 15 to 60 years) with Philadelphia chromosome–negative ALL were enrolled onto the Group for Research on Adult Acute Lymphoblastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results